In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas
The article reviews current literature on the use of adoptive immunotherapy for malignant gliomas as well as the
the concept of antitumor activity mediated by CIK cells.
Immunotherapy for glioblastoma has been an area of intense research in recent years – this review looks at the potential of HCMV in the initiation, promotion and progression of tumorigenesis.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.
This Spotlight will explore every corner of neuroimmunology, looking in-depth at the history of the field, new uses for the immune system in a wealth of neurological diseases, and looking ahead at the future of this ever-expanding field.
Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.
This article reviews new vaccination protocols against glioblastoma, as well as new the prospect of novel combination therapies.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.